Thus, CD99 was used as a marker for detecting minimal residual disease (MRD) of T-ALL and was proposed to be a promising target for antibody treatment of T cell malignancy [30,31,32]. The gene discussed is CD99; the disease is acute lymphoblastic leukemia.